Nabriva Therapeutics plc Proceeds from Common Stock Issued
Nabriva Therapeutics plc reported Proceeds from Common Stock Issued of $3.46 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-04-17.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2023-10-19
- Nabriva Therapeutics plc proceeds from issuance of common stock for the quarter ending 2022-12-31 was $380.00K.
- Nabriva Therapeutics plc proceeds from issuance of common stock for the quarter ending 2022-09-30 was $2.09M, a 51.58% decline year-over-year.
- Nabriva Therapeutics plc proceeds from issuance of common stock for the quarter ending 2022-06-30 was $398.00K, a 98.48% decline year-over-year.
- Nabriva Therapeutics plc proceeds from issuance of common stock for the quarter ending 2022-03-31 was $595.00K, a 94.97% decline year-over-year.
- Nabriva Therapeutics plc proceeds from issuance of common stock for fiscal 2022 was $3.46M, a 91.82% decline from fiscal 2021.
- Nabriva Therapeutics plc proceeds from issuance of common stock for fiscal 2021 was $42.28M, a 462.23% increase from fiscal 2020.
- Nabriva Therapeutics plc proceeds from issuance of common stock for fiscal 2020 was $7.52M, a 73.09% decline from fiscal 2019.
- Nabriva Therapeutics plc proceeds from issuance of common stock for fiscal 2019 was $27.95M, a 15.38% increase from fiscal 2018.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|
| 2022-12-31 | $380.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | $2.47M derived: sum of 2 quarters · filed 2023-04-17 | $2.87M derived: sum of 3 quarters · filed 2023-10-19 | $3.46M 10-K · filed 2023-04-17 |
| 2022-09-30 | $2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.48M derived: sum of 2 quarters · filed 2023-10-19 | $3.08M 10-Q · filed 2022-11-10 | $3.08M derived: sum of 4 quarters · filed 2023-10-19 |
| 2022-06-30 | $398.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-10-19 | $993.00K 10-Q · filed 2023-10-19 | $993.00K derived: sum of 3 quarters · filed 2023-10-19 | $5.30M derived: sum of 4 quarters · filed 2023-10-19 |
| 2022-03-31 | $595.00K 10-Q · filed 2023-05-22 | $595.00K derived: sum of 2 quarters · filed 2023-05-22 | $4.91M derived: sum of 3 quarters · filed 2023-05-22 | $31.05M derived: sum of 4 quarters · filed 2023-05-22 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | $4.31M derived: sum of 2 quarters · filed 2023-04-17 | $30.45M derived: sum of 3 quarters · filed 2023-04-17 | $42.28M 10-K · filed 2023-04-17 |
| 2021-09-30 | $4.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $30.45M derived: sum of 2 quarters · filed 2022-11-10 | $42.28M 10-Q · filed 2022-11-10 | $42.68M derived: sum of 4 quarters · filed 2023-04-17 |
| 2021-06-30 | $26.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $37.97M 10-Q · filed 2022-08-03 | $38.37M derived: sum of 3 quarters · filed 2023-04-17 | $41.80M derived: sum of 4 quarters · filed 2023-04-17 |
| 2021-03-31 | $11.83M 10-Q · filed 2022-05-05 | $12.23M derived: sum of 2 quarters · filed 2023-04-17 | $15.66M derived: sum of 3 quarters · filed 2023-04-17 | $19.20M derived: sum of 4 quarters · filed 2023-04-17 |
| 2020-12-31 | $401.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | $3.83M derived: sum of 2 quarters · filed 2023-04-17 | $7.37M derived: sum of 3 quarters · filed 2023-04-17 | $7.52M 10-K · filed 2023-04-17 |
| 2020-09-30 | $3.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $6.96M derived: sum of 2 quarters · filed 2021-11-09 | $7.12M 10-Q · filed 2021-11-09 | $11.88M derived: sum of 4 quarters · filed 2022-03-29 |
| 2020-06-30 | $3.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $3.69M 10-Q · filed 2021-08-05 | $8.44M derived: sum of 3 quarters · filed 2022-03-29 | |
| 2020-03-31 | $154.00K 10-Q · filed 2021-05-06 | $4.91M derived: sum of 2 quarters · filed 2022-03-29 | ||
| 2019-12-31 | $4.76M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $27.95M 10-K · filed 2022-03-29 | ||
| 2019-09-30 | $23.19M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $1.44M derived: sum of 2 quarters · filed 2021-03-11 | $4.83M derived: sum of 3 quarters · filed 2021-03-11 | $24.22M 10-K · filed 2021-03-11 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $3.40M derived: sum of 2 quarters · filed 2018-11-06 | $22.78M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $3.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $22.78M 10-Q · filed 2018-08-09 | ||
| 2018-03-31 | $19.39M 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | $24.82M 10-K · filed 2018-03-16 |